pharmaceutical research

President Trump is accelerating research into psychedelic drugs as mental health treatments, creating new regulatory pathways for pharmaceutical development. This policy shift opens opportunities for biotech companies developing psychedelic-based therapies while introducing regulatory uncertainties.